RxDoctor Payments Data

Kieran Hynes, MD

Urology · Jackson, MSNPI 1235629973

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,597, more than ten times the $145 reported in 2019.

$5,723in general payments, 2019–2025

Across 159 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Johnson & Johnson$873
  • Dendreon Pharmaceuticals LLC$723
  • Urogen Pharma, Inc.$542
  • Astellas Pharma US Inc$293
  • Myriad Genetic Laboratories, Inc.$276
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,60198%
  • Education$1222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,723 in reported general payments places this provider in the 65th percentile of 94 urology providers in Mississippi.

See all urology providers in Mississippi

Medicare billing

Part B allowed, 2024
$203,357
Medicare patients
419
Services billed
5,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$269,450
Tamsulosin Hcl154$1,550
Estradiol12$1,061
Oxybutynin Chloride ErOxybutynin Chloride26$476
Finasteride40$403
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$324
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$262
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$124
Ciprofloxacin Hcl33$117
Cephalexin19$99
Oxybutynin Chloride12$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$293$269,45020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 urology providers in Mississippi.

Other urology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →